Loading organizations...
§ Private Profile · Redwood City, CA, USA
Biotech company develops affordable, scalable DNA sequencing technology with electronic detection for genomic testing and medical sequencing.
Genapsys is a Redwood City, California-based biotechnology company that develops scalable DNA sequencing hardware and electronic detection systems for genomic testing and medical research. The organization targets research institutions, pharmaceutical firms, and the estimated 400,000 global molecular laboratories lacking sequencing equipment by offering compact tabletop sequencers priced at $9,995. Generating revenue through device sales and ongoing consumable supplies, the enterprise has raised approximately $250 million in total venture funding to support its commercialization and manufacturing efforts. Genapsys is backed by institutional investors including Oxford Finance, Foresite Capital, and Decheng Capital, while its technology development has been guided by prominent scientific advisors such as George Church and Eric Topol. The company was originally founded in 2010 by Hesaam Esfandyarpour to commercialize electronic sequencing technologies initially developed during his academic research at Stanford University.
Genapsys has raised $280.5M across 5 funding rounds.
Genapsys has raised $280.5M in total across 5 funding rounds.
Genapsys has raised $280.5M across 5 funding rounds. Most recently, it raised $70.0M Series D in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 27, 2021 | $70M Series D | — | Farallon Capital Management, Soleus Capital | Announced |
| Feb 7, 2020 | $75M Venture Round | Oxford Finance | — | Announced |
| Nov 20, 2019 | $90M Series C | JIM Tananbaum | — | Announced |
| Nov 15, 2013 | $37M Series B | — | Yuri Milner, Decheng Capital, IPV, Stanford | Announced |
| Mar 22, 2013 | $8.5M Venture Round | — | — | Announced |
Genapsys has raised $280.5M in total across 5 funding rounds.
Genapsys's investors include Farallon Capital Management, Soleus Capital, Oxford Finance, Jim Tananbaum, Yuri Milner, Decheng Capital, IPV, Stanford.